Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

AnaptysBio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WASHINGTON , DEC. 15, 2025 /PRNEWSWIRE/ --VANDA PHARMACEUTICALS INC. (VANDA) (NASDAQ: VNDA) TODAY ANNOUNCED THE SUBMISSION OF A BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR IMSIDOLIMAB, A NOVEL IGG4 IL-36 RECEPTOR ANTAGONIST, TO TREAT GENERALIZED PUSTULAR PSORIASIS (GPP). IMSIDOLIMAB INHIBITS IL-36 RECEPTOR SIGNALING, ADDRESSING THE DEFICIENCY IN THE ENDOGENOUS IL-36RA REGULATOR COMMONLY SEEN IN GPP PATIENTS DUE TO IL36RN GENE MUTATIONS.

VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS

SAN DIEGO, NOV. 25, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT DANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS, AND/OR OTHER MEMBERS OF ITS EXECUTIVE LEADERSHIP TEAM, ARE SCHEDULED TO PARTICIPATE IN MULTIPLE UPCOMING INVESTOR CONFERENCES:

ANAPTYS ANNOUNCES PARTICIPATION IN DECEMBER INVESTOR CONFERENCES

SAN DIEGO, NOV. 21, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED AN AMENDED STOCK REPURCHASE PLAN UNDER WHICH THE COMPANY MAY REPURCHASE UP TO $100.0 MILLION OF THE COMPANY'S OUTSTANDING COMMON STOCK, PAR VALUE $0.001 PER SHARE. THIS AMENDMENT IS IN ADDITION TO THE $6.4 MILLION THAT REMAINED AS OF NOV. 20, 2025 UNDER THE CURRENT $75.0 MILLION STOCK REPURCHASE PLAN OF WHICH ANAPTYS HAS REPURCHASED A TOTAL OF 3,443,188 SHARES OF COMMON STOCK (11.2% SHARES OUTSTANDING BEFORE THE START OF THIS REPURCHASE PLAN). EXCLUDING ANY ADDITIONAL POTENTIAL PURCHASES UNDER THIS STOCK REPURCHASE PLAN, ANAPTYS ANTICIPATES ENDING 2025 WITH APPROXIMATELY $300 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS, INCLUDING AN ANTICIPATED ACCRUAL OF A ONE-TIME $75 MILLION COMMERCIAL SALES MILESTONE IN Q4 2025 DUE FROM GSK ONCE JEMPERLI ACHIEVES $1 BILLION IN WORLDWIDE NET SALES.

ANAPTYS ANNOUNCES $100 MILLION STOCK REPURCHASE PLAN

SAN DIEGO, NOV. 21, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, ANNOUNCED IT HAS FILED A VERIFIED COMPLAINT IN DELAWARE CHANCERY COURT, REQUESTING A COURT DECLARATION THAT TESARO, INC. (TESARO) HAS MATERIALLY BREACHED THE PARTIES' COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (COLLABORATION AGREEMENT) AND THAT GSK (TESARO'S CORPORATE PARENT) HAS TORTIOUSLY INTERFERED WITH THE COLLABORATION AGREEMENT. ANAPTYS HAS REQUESTED THAT THE COURT DECLARE THAT ANAPTYS IS ENTITLED TO ALL RIGHTS AND REMEDIES UNDER THE COLLABORATION AGREEMENT.

ANAPTYS INITIATES LITIGATION AGAINST TESARO, A GSK SUBSIDIARY

ROSNILIMAB WAS SAFE AND WELL TOLERATED WITH SIMILAR ADVERSE EVENT RATES VS. PLACEBO OBSERVED EXPECTED PHARMACOLOGY, INCLUDING ~90% DEPLETION OF PATHOGENIC T CELLS, HOWEVER LACK OF ADEQUATE EFFICACY AT WEEK 12 DOES NOT SUPPORT FURTHER DEVELOPMENT OF ROSNILIMAB IN UC AND TRIAL WILL BE DISCONTINUED, RESULTING IN AT LEAST $10 MILLION IN SAVINGS WILL PROVIDE UPDATE IN H1 2026 ON ADVANCEMENT OF ROSNILIMAB IN RA, WHICH WOULD BE FUNDED BY STRATEGIC OR OTHER SOURCES OF CAPITAL WITHOUT DILUTING OUR ROYALTIES REITERATING COMMITMENT TO PROTECT AND RETURN THE VALUE OF OUR SUBSTANTIAL ROYALTIES TO SHAREHOLDERS AND INTENTION TO SEPARATE BIOPHARMA OPERATIONS FROM ROYALTY ASSETS IN 2026 BIOPHARMA CO WILL ADVANCE ANB033 THROUGH PHASE 1B IN CELIAC DISEASE AND AN ADDITIONAL INFLAMMATORY INDICATION, AND ANB101 THROUGH PHASE 1A IN HEALTHY VOLUNTEERS ANTICIPATE ENDING 2025 WITH ~$300 MILLION, INCLUDING ANTICIPATED ACCRUAL OF ONE-TIME $75 MILLION COMMERCIAL SALES MILESTONE FROM GSK IN Q4 2025 ONCE JEMPERLI ACHIEVES $1 BILLION IN GLOBAL NET SALES SAN DIEGO, NOV. 10, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT INVESTIGATIONAL ROSNILIMAB WAS SAFE AND WELL TOLERATED BUT DID NOT MEET THE PRIMARY ENDPOINT OF MEAN CHANGE FROM BASELINE IN MODIFIED MAYO SCORE (MMS) OR KEY SECONDARY ENDPOINTS OF CLINICAL RESPONSE AND CLINICAL REMISSION AT WEEK 12 IN THE GLOBAL PHASE 2 TRIAL FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC).

ANAPTYS ANNOUNCES PHASE 2 TRIAL OF ROSNILIMAB DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS AT WEEK 12 IN MODERATE-TO-SEVERE ULCERATIVE COLITIS

ANNOUNCED INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YE 2026 PHASE 2 TOP-LINE DATA THROUGH WEEK 12 FOR ROSNILIMAB, A PATHOGENIC T CELL DEPLETER, IN ULCERATIVE COLITIS ON TRACK FOR NOV./DEC. 2025 PHASE 2B DATA FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS FEATURED AS LATE-BREAKING ORAL PRESENTATION AT ACR CONVERGENCE 2025 PHASE 1B INITIATED IN CELIAC DISEASE FOR ANB033, A CD122 ANTAGONIST; TOP-LINE PHASE 1B DATA ANTICIPATED IN Q4 2026 GSK ANNOUNCED STRONG COMMERCIAL PERFORMANCE FOR JEMPERLI, GROWING >16% QUARTER-OVER-QUARTER TO $303 MILLION IN Q3 2025 AND $785 MILLION YTD 2025 ANAPTYS ANTICIPATES ACCRUING A ONE-TIME $75 MILLION COMMERCIAL SALES MILESTONE IN Q4 2025 FROM GSK ONCE JEMPERLI ACHIEVES $1 BILLION IN WORLDWIDE NET SALES >$390 MILLION IN ANNUALIZED JEMPERLI ROYALTIES PAYABLE TO ANAPTYS AT GSK'S PEAK SALES GUIDANCE OF >$2.7 BILLION, WHICH ANAPTYS EXPECTS TO BE ACHIEVED BEFORE 2031 SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE. OUR INTENT TO SEPARATE OUR WHOLLY OWNED BIOPHARMA PROGRAMS FROM OUR ROYALTY ASSETS PROVIDES INVESTORS WITH THE OPPORTUNITY TO REALIZE AND ENHANCE THE POTENTIAL VALUE OF TWO DISTINCT SETS OF ASSETS.

ANAPTYS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT DANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS, AND/OR OTHER MEMBERS OF ITS EXECUTIVE LEADERSHIP TEAM, ARE SCHEDULED TO PARTICIPATE IN MULTIPLE UPCOMING INVESTOR CONFERENCES: TD COWEN IMMUNOLOGY & INFLAMMATION SUMMIT, VIRTUAL FORMAT  FIRESIDE CHAT DATE AND TIME  WEDNESDAY, NOV. 12, 2025 AT 8:00AM ET GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE, BOSTON, MA FORMAT  FIRESIDE CHAT AND 1X1 INVESTOR MEETINGS DATE AND TIME  WEDNESDAY, NOV. 12, 2025 AT 11:30AM ET STIFEL 2025 HEALTHCARE CONFERENCE, NEW YORK, NY FORMAT  FIRESIDE CHAT AND 1X1 INVESTOR MEETINGS DATE AND TIME  THURSDAY, NOV. 13, 2025 AT 1:20PM ET JEFFERIES GLOBAL HEALTHCARE CONFERENCE, LONDON, UK FORMAT  PRESENTATION AND 1X1 INVESTOR MEETINGS DATE AND TIME  MONDAY, NOV. 17, 2025 AT 4:00PM GMT LIVE WEBCASTS OF THE FIRESIDE CHATS AND PRESENTATION WILL BE AVAILABLE ON THE INVESTOR SECTION OF THE ANAPTYS WEBSITE ATHTTPS://IR.ANAPTYSBIO.COM/PRESENTATIONS-AND-EVENTS. REPLAYS OF THE WEBCASTS WILL BE AVAILABLE FOR AT LEAST 30 DAYS FOLLOWING THE EVENTS.

ANAPTYS ANNOUNCES PARTICIPATION IN NOVEMBER INVESTOR CONFERENCES

SAN DIEGO, OCT. 29, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED LATE-BREAKING DATA FROM THE ROBUST, GLOBAL 424-PATIENT PHASE 2B TRIAL OF ROSNILIMAB, A SELECTIVE AND POTENT PATHOGENIC T CELL DEPLETER, IN RHEUMATOID ARTHRITIS (RA) AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 IN CHICAGO. NEW STUDY RESULTS SHOWED THAT POSITIVE WEEK 12 DATA ACROSS MULTIPLE HIGHER-ORDER RESPONSE MEASURES CONTINUE TO DEEPEN INTO WEEK 28 REGARDLESS OF PRIOR TREATMENT. THESE RESULTS WERE THEN DURABLE FOR AT LEAST THREE MONTHS OFF DRUG. ADDITIONALLY, ROSNILIMAB WAS WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND NO MALIGNANCIES IN ROSNILIMAB-TREATED PATIENTS THROUGH END-OF-TRIAL FOLLOW-UP (WEEK 38).

ANAPTYS ANNOUNCES NEW POSITIVE PHASE 2B TRIAL RESULTS FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT ACR LATE-BREAKING ORAL PRESENTATION

SAN DIEGO, OCT. 13, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT COMPLETE DATA FROM THE PHASE 2B TRIAL OF ROSNILIMAB, A PATHOGENIC T CELL DEPLETER, IN RHEUMATOID ARTHRITIS (RA), WAS ACCEPTED FOR A LATE-BREAKING ORAL PRESENTATION AT AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 IN CHICAGO, IL, OCT. 24  29, 2025.

ANAPTYS ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF COMPLETE PHASE 2B DATA FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT UPCOMING ACR CONVERGENCE 2025

SAN DIEGO, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED IT WILL HOST A VIRTUAL INVESTOR EVENT ON ANB033, ITS CD122 ANTAGONIST, AT 4:30PM ET / 1:30PM PT ON TUESDAY, OCT. 14.

ANAPTYS TO PROVIDE OVERVIEW OF ANB033, A CD122 ANTAGONIST, AT VIRTUAL INVESTOR EVENT ON TUESDAY, OCT. 14

SAN DIEGO, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS APPROVED PLANS TO EXPLORE SEPARATING ITS BUSINESS INTO TWO INDEPENDENT, PUBLICLY TRADED COMPANIES, EACH POISED FOR STRONG, SUSTAINABLE GROWTH. REFERRED TO AS ROYALTY MANAGEMENT CO AND AS BIOPHARMA CO IN THIS PRESS RELEASE, THE TWO COMPANIES' DIFFERENT BUSINESS MODELS ENABLE INVESTORS TO ALIGN THEIR INVESTMENT PHILOSOPHIES AND PORTFOLIO ALLOCATION WITH THE STRATEGIC OPPORTUNITIES AND FINANCIAL OBJECTIVES OF EACH COMPANY. ANAPTYS IS STRATEGICALLY POSITIONED WITH MULTIPLE ATTRACTIVE, HIGH-POTENTIAL ASSETS, INCLUDING OUR DEVELOPMENT-STAGE PIPELINE CONSISTING OF ROSNILIMAB, ANB033 AND ANB101, AS WELL AS SUBSTANTIAL POTENTIAL ROYALTIES AND MILESTONES PAYMENTS FROM OUR ONGOING FINANCIAL COLLABORATIONS WITH GSK AND VANDA, SAID DANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS. IN PARALLEL WITH ASSESSING MULTIPLE STRATEGIC OPTIONS FOR ROSNILIMAB IN RA OR UC, INCLUDING SECURING A GLOBAL PARTNERSHIP TO HELP ADVANCE DEVELOPMENT IN ALL INDICATIONS OR ADVANCING IN ONE PHASE 3 INDICATION INDEPENDENTLY, TODAY'S ANNOUNCEMENT TO EXPLORE A SEPARATION OF OUR WHOLLY OWNED BIOPHARMA PROGRAMS FROM OUR ROYALTY ASSETS IS INTENDED TO PROVIDE INVESTORS WITH THE OPPORTUNITY TO REALIZE AND ENHANCE THE POTENTIAL VALUE OF TWO DISTINCT SETS OF ASSETS. ROYALTY MANAGEMENT CO PROFILE

AnaptysBio, Inc.

ANAB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AnaptysBio, Inc.

ANAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ANAB